Hepcidin and Anemia in Trauma

Completed

Conditions studied: Anemia

In brief

Anemia (decreased number of red blood cells) is common in critically ill trauma patients admitted to an Intensive Care Unit and is associated with a high rate of blood transfusions. This "anemia of inflammation" is a result of three mechanisms: impaired iron regulation, shortened red blood cell life span, and reduced rate of erythropoiesis (a protein that helps make new red blood cells). Hepcidin, a protein made in the liver, regulates iron and is decreased when iron in the blood is low. This can lead to anemia. This research study is being conducted to learn how inflammation, hepcidin, and erythropoietin interact in critically ill patients. The findings will help in determining effective treatment for patients with anemia of inflammation.

Key facts

Study ID

NCT01580267

Run by

University of Michigan

People needed

74

Starts

2012-06-01

Expected to finish

2014-04-01

Last updated by the study team

2014-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Trauma patient
• Age 18 years or older
• Admitted to ICU
• Anemic (Hct < 34.5%)

You may not qualify if…

• Pre-existing hematological disorder
• Pre-existing diagnosis of anemia or other known iron disorder
• Chronic renal failure
• Use of recombinant erythropoietin
• Treatment with systemic immunosuppressant or cytotoxic drugs
• Pregnancy
• Patients not expected to survive

Where it is running

• University of Michigan Health System — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.